Search

Displaying results 3731 - 3740 of 10000 in total
  1. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. ANA971 is a prodrug designed to improve the oral bioavailability of isatoribine.

  2. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Acipimox is a niacin derivative used as a hypolipidemic agent. … It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid.

    Categories: Heterocyclic Compounds, 1-Ring
  3. Drug

    Sitamaquine

    go.drugbank.com/drugs/DB04909
    Investigational

    Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential

    Categories: Heterocyclic Compounds, 2-Ring
  4. Drug

    NBI-6024

    go.drugbank.com/drugs/DB05819
    Investigational

    NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.

  5. Drug

    SSR-126517E

    go.drugbank.com/drugs/DB05362
    Experimental

    SSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.

  6. Drug

    Isatoribine

    go.drugbank.com/drugs/DB04860
    Experimental

    Isatoribine is a selective agonist of TLR7.

    Synonyms: 7-Deaza-7-thia-8-oxoguanosine, 7-Thia-8-oxoguanosineCategories: Heterocyclic Compounds, 2-Ring
  7. Drug

    ZYC300

    go.drugbank.com/drugs/DB04986
    Investigational

    ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles. … It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.

  8. Drug

    Resiquimod

    go.drugbank.com/drugs/DB06530
    Investigational

    It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator. … A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells.

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    Sodium borate

    go.drugbank.com/drugs/DB14505
    Approved

  10. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: TASIGNA® 150 MG CAPSULAS